The Issue of Tissue in Molecular Stratification

Affiliations

Comment

Min-Han Tan et al. Oncologist. 2017 Dec.

. 2017 Dec;22(12):1560.

doi: 10.1634/theoncologist.2017-0165. Epub 2017 Sep 11.

Abstract

This letter reflects on the importance of external validation, in real‐world settings, for clinical application.

In Reply.
de Velasco G, Culhane AC, Heng DYC, Signoretti S, Choueiri TK. de Velasco G, et al. Oncologist. 2017 Dec;22(12):1561. doi: 10.1634/theoncologist.2017-0283. Epub 2017 Sep 11. Oncologist. 2017. PMID: 28894018 Free PMC article.

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK. de Velasco G, et al. Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20. Oncologist. 2017. PMID: 28220024 Free PMC article.

1. de Velasco G, Culhane AC, Fay AP et al. Molecular subtypes improve prognostic value of International Metastatic Renal Cell Carcinoma Database Consortium prognostic model. The Oncologist 2017;22:286–292. - PMC - PubMed
1. Brooks SA, Brannon AR, Parker JS et al. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77–84. - PMC - PubMed
1. Choudhury Y, Wei X, Chu YH et al. A multigene assay identifying distinct prognostic subtypes of clear cell renal cell carcinoma with differential response to tyrosine kinase inhibition. Eur Urol 2015;67:17–20. - PubMed
1. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43–49. - PMC - PubMed
1. Wei X, Choudhury Y, Lim WK et al. Recognizing the continuous nature of expression heterogeneity and clinical outcomes in clear cell renal cell carcinoma. Sci Rep 2017;7:7342. - PMC - PubMed